PROLIA (also known as Denosumab)

Mechanism:

Prolia is an antibody that inhibits RANK-Ligand, which leads to the protection of bone mass from degradation.

Indications:

• Treatment for Postmenopausal women with osteoporosis at high risk for fracture
• Treatment to increase bone mass in men at high risk for fracture
• Prophylaxis for patients receiving androgen deprivation therapy for nonmetastatic prostate cancer
• Treatment to increase bone mass in women at high risk for fracture
• Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

Contraindications:

Patients with hypocalcemia, especially with concurrent renal impairment, should consult their physicians and have their calcium levels corrected before initiating Prolia.

Administration:

Prolia is typically administered as a subcutaneous injection by a healthcare professional every 6 months.